Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus-Friedrich Bodmann

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Deutsche Medizinische Wochenschrift (1946)|June 5, 2019
[The 2018 Update of the Recommendations of the Paul-Ehrlich-Society for Chemotherapy on the Initial Parenteral Therapy of Bacterial Diseases in Adults - What's relevant for Intensive Care?]Klaus-Friedrich Bodmann
GMS Infectious Diseases|December 30, 2020
Clinical and economical improvements after introducing rapid identification of bacteria and early antibiotic susceptibility testing in sepsis and bloodstream infections. Results of the PHENOMENON studyMichael Wilke, Wolfgang Heinlein, Luis Stiefenhofer, et al.
Medizinische Klinik (Munich, Germany : 1983)|June 22, 2005
[Abbreviated guidelines for prevention, diagnostics, and therapy of nosocomial pneumonia]Torsten T Bauer, Joachim Lorenz, Klaus-Friedrich Bodmann, et al.
GMS Infectious Diseases|May 7, 2020
Calculated initial parenteral treatment of bacterial infections: SepsisKlaus-Friedrich Bodmann, Rainer Höhl, Wolfgang Krüger, et al.
GMS Infectious Diseases|May 7, 2020
Calculated initial parenteral treatment of bacterial infections: Bacterial endocarditisPascal M Dohmen, Klaus Friedrich Bodmann, Wolfgang Graninger, et al.
GMS Infectious Diseases|May 7, 2020
Calculated parenteral initial treatment of bacterial infections: Introduction and antibioticsKlaus-Friedrich Bodmann, Michael Kresken, Béatrice Grabein, et al.
GMS Infectious Diseases|November 16, 2019
Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG dataMichael Wilke, Kerstin Worf, Birgit Preisendörfer, et al.
Chemotherapy|July 23, 2011
Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practiceChristian Eckmann, Wolfgang R Heizmann, Eva Leitner, et al.
Surgical Infections|June 27, 2015
Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant BacteriaChristian Eckmann, Wolfgang Heizmann, Klaus-Friedrich Bodmann, et al.
Chemotherapy|October 12, 2012
Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalitiesKlaus-Friedrich Bodmann, Wolfgang R Heizmann, Christof von Eiff, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Deutsche Medizinische Wochenschrift (1946)|June 5, 2019
[The 2018 Update of the Recommendations of the Paul-Ehrlich-Society for Chemotherapy on the Initial Parenteral Therapy of Bacterial Diseases in Adults - What's relevant for Intensive Care?]Klaus-Friedrich Bodmann
GMS Infectious Diseases|December 30, 2020
Clinical and economical improvements after introducing rapid identification of bacteria and early antibiotic susceptibility testing in sepsis and bloodstream infections. Results of the PHENOMENON studyMichael Wilke, Wolfgang Heinlein, Luis Stiefenhofer, et al.
Medizinische Klinik (Munich, Germany : 1983)|June 22, 2005
[Abbreviated guidelines for prevention, diagnostics, and therapy of nosocomial pneumonia]Torsten T Bauer, Joachim Lorenz, Klaus-Friedrich Bodmann, et al.
GMS Infectious Diseases|May 7, 2020
Calculated initial parenteral treatment of bacterial infections: SepsisKlaus-Friedrich Bodmann, Rainer Höhl, Wolfgang Krüger, et al.
GMS Infectious Diseases|May 7, 2020
Calculated initial parenteral treatment of bacterial infections: Bacterial endocarditisPascal M Dohmen, Klaus Friedrich Bodmann, Wolfgang Graninger, et al.
GMS Infectious Diseases|May 7, 2020
Calculated parenteral initial treatment of bacterial infections: Introduction and antibioticsKlaus-Friedrich Bodmann, Michael Kresken, Béatrice Grabein, et al.
GMS Infectious Diseases|November 16, 2019
Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG dataMichael Wilke, Kerstin Worf, Birgit Preisendörfer, et al.
Chemotherapy|July 23, 2011
Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practiceChristian Eckmann, Wolfgang R Heizmann, Eva Leitner, et al.
Surgical Infections|June 27, 2015
Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant BacteriaChristian Eckmann, Wolfgang Heizmann, Klaus-Friedrich Bodmann, et al.
Chemotherapy|October 12, 2012
Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalitiesKlaus-Friedrich Bodmann, Wolfgang R Heizmann, Christof von Eiff, et al.
Pageof 2